TEL AVIV, Israel, September 9, 2016 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ/TASE : BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will host an investor breakfast meeting on Thursday, September 22, 2016 at the Convene Conference Center near Grand Central in New York, NY.
The agenda and topics for discussion include: (i) an overview of BL-8040, the Company's lead program in oncology, with an emphasis on the cancer immunotherapy collaborations with Genentech and Merck, and the development and commercialization plans in stem-cell mobilization; (ii) a keynote presentation by Dr. Manuel Hidalgo, an internationally renowned key opinion leader in pancreatic cancer and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center, an affiliate of Harvard University in Boston; (iii) an overview of the Company's plans for 2017; and (iv) a review of the Company's key mid-term objectives over the next five years.
The investor meeting schedule is as follows:
- 8:30am EDT - Registration
- 9:00-10:30am EDT - Formal Presentations and Q&A
Convene Conference Center
101 Park Avenue near Grand Central
New York, NY
BioLineRx Ltd. will also host a live audio webcast of the investor breakfast. To access the webcast, please go to the breakfast event page on BioLineRx's website. It is recommended that users register 15 minutes prior to the scheduled start time to ensure timely connection. An audio replay of the meeting will also be available for approximately three months following the meeting on the breakfast event page.
Registration and Additional Information
Advanced registration is required for onsite attendance. To register, please contact Vivian Cervantes at firstname.lastname@example.org.
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment, and has recently initiated a Phase 2 study in stem cell mobilization for allogeneic transplantation; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA®; and has recently signed a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's Atezolizumab in several Phase 1b studies for multiple solid tumor indications and AML.
For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.
Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2016. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.
SOURCE BioLineRx Ltd.